...
首页> 外文期刊>Advances in cell and gene therapy. >Important aspects of T‐cell collection by apheresis for manufacturing chimeric antigen receptor T cells
【24h】

Important aspects of T‐cell collection by apheresis for manufacturing chimeric antigen receptor T cells

机译:在生产嵌合抗原受体T细胞中,通过格式收集T细胞收集的重要方面

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Chimeric antigen receptor (CAR)‐T cells have proven to be an effective cancer therapy for CD19‐expressing neoplasms. Efforts to optimize the manufacturing process can help to ensure the efficacy and safety of the therapy. Peripheral blood T cells, which serve as the source material, are collected by apheresis. However, the majority of apheresis collection protocols do not selectively collect T cells, but rather isolate the mononuclear cell (MNC) layer, which also contains other mononuclear leukocytes present in the peripheral blood. Since currently CAR‐T cells are autologous, the patient's clinical condition is a major factor in the planning, coordination, and execution of the apheresis procedure to subsequently manufacture the product successfully. Efforts have been made to identify predictors of a successful collection (ie, precollection peripheral blood CD3+ count). The characteristics of the source material influences the manufacturing process directly, and therefore affects the quantity, viability, immune cell composition, and T cell phenotypic makeup of the final product. Here we review the CAR‐T cell manufacturing process from the apheresis perspective, highlighting considerations before, during, and after collection that could potentially alter the outcome of the manufacturing process and ultimately, the safety and efficacy of the therapy for the patient.
机译:摘要嵌合抗原受体(CAR)-T细胞已被证明是表达CD19肿瘤的有效癌症治疗。优化制造过程的努力可以帮助确保治疗的功效和安全性。外周血T细胞用作原始材料,是通过格言收集的。然而,大多数格式收集方案不能选择性地收集T细胞,而是分离单核细胞(MNC)层,该层还包含外周血中存在的其他单核白细胞。由于目前的CAR -T细胞是自体的,因此患者的临床状况是置于磨牙程序的计划,协调和执行的主要因素,以便成功地生产产品。已经努力确定成功收集的预测因子(即,前填层外周血CD3+计数)。源材料的特征直接影响制造过程,因此影响最终产物的数量,活力,免疫细胞组成和T细胞表型构成。在这里,我们从刻度上的角度回顾了CAR -T细胞制造过程,突出了可能会改变制造过程结果的考虑,并最终会改变患者治疗的安全性和功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号